RecruitingNot ApplicableNCT07400757

Statin and Vitamin D Treatment in Patients With Thyroid Eye Disease

The Role of Statin and Vitamin D for the Treatment of Thyroid Eye Disease


Sponsor

Taipei Veterans General Hospital, Taiwan

Enrollment

120 participants

Start Date

Feb 24, 2026

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this clinical trial is to learn whether statin therapy and vitamin D supplementation can modify disease activity in patients with active thyroid eye disease. The study will also evaluate the safety of these treatments. The main questions it aims to answer are: * Does statin therapy change disease activity, as measured by changes in the Clinical Activity Score (CAS) and proptosis? * Does vitamin D supplementation change disease activity in patients with active thyroid eye disease? * Does combined treatment with statin and vitamin D produce different effects compared with either treatment alone or standard care? * What adverse events occur during treatment? Researchers will compare four groups: standard care alone, statin therapy plus standard care, vitamin D supplementation plus standard care, and combined statin and vitamin D therapy plus standard care. Participants will: * Be randomly assigned to one of four treatment groups * Receive the assigned treatment for 24 weeks * Attend clinic visits for clinical assessments and blood tests at baseline and at 24 weeks * Be followed through medical record review for up to three years after completion of the intervention


Eligibility

Min Age: 20 Years

Inclusion Criteria3

  • Adults aged 20 years or older
  • Diagnosis of active thyroid eye disease with a Clinical Activity Score (CAS) of 3 or higher
  • Low-density lipoprotein cholesterol (LDL-C) level of 100 mg/dL or higher

Exclusion Criteria4

  • Prior orbital radiotherapy or orbital surgery for thyroid eye disease
  • Use of statins or high-dose vitamin D supplementation (greater than 400 IU per day) within 3 months prior to enrollment
  • Pregnancy
  • Severe renal impairment, defined as an estimated glomerular filtration rate (eGFR) less than 30 mL/min/1.73 m²

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAtorvastatin (Lipitor)

Oral atorvastatin 20 mg administered once daily for 24 weeks.

DIETARY_SUPPLEMENTVitamin D

Oral vitamin D supplementation at a dose of 1400 IU administered once daily for 24 weeks.


Locations(1)

Taipei Veterans General Hospital

Taipei, Taiwan, Taiwan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07400757


Related Trials